Webinar covers the benefits of generative AI in drug discovery
In this webinar, discover how high-performance computing (HPC) and AI are being used to screen out potentially dangerous drugs, improve the identification of drug candidates, and develop new therapeutic compounds.
It can take years, and cost billions, to get new drugs approved for clinical use, but technological advances are transforming drug discovery and development. The growing shift towards artificial intelligence (AI), including generative and predictive AI, can reduce the amount of time and money it takes to develop new drugs. It offers the potential to drastically shorten the early stages of drug discovery and help identify future drug candidates faster.
The webinar will take place on Tuesday 28 January 2025 at 10am GMT / 11am CET.
You will hear from Dr Marissa Powers, Solutions Architect, High Performance Computing (HPC) Life Sciences at Amazon Web Services (AWS), and Dr David Ruau, EMEA Business Development Lead, Healthcare and Life Sciences at NVIDIA.
What you’ll learn:
- How to overcome common challenges from data quality, managing multi-modal data, and limited computational resources
- How generative AI is impacting and accelerating the drug discovery process
- How accelerated computing and purpose-built tools can help build, run, and train generative AI workloads